PriceTargets.com logo

BiomX - PHGE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $22.50
  • Forecasted Upside: 3,529.03%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.62 As of 12/20/2024 01:00 AM ET
▲ +0.0506 (8.89%)

This chart shows the closing price for PHGE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BiomX Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PHGE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PHGE

Analyst Price Target is $22.50
▲ +3,529.03% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for BiomX in the last 3 months. The average price target is $22.50, with a high forecast of $25.00 and a low forecast of $20.00. The average price target represents a 3,529.03% upside from the last price of $0.62.

This chart shows the closing price for PHGE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in BiomX. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/2/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
5/28/2024LaidlawInitiated CoverageBuy$25.00
5/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00
4/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00
8/9/2023HC WainwrightReiterated RatingBuy$70.00
5/15/2023HC WainwrightLower Target$100.00 ➝ $70.00
11/10/2022Cantor FitzgeraldReiterated RatingOverweight
11/9/2022Chardan CapitalLower TargetBuy$60.00 ➝ $20.00
5/12/2022LADENBURG THALM/SH SHLower Target$130.00 ➝ $80.00
3/31/2022Chardan CapitalLower Target$130.00 ➝ $120.00
11/16/2021Chardan CapitalLower TargetBuy$160.00 ➝ $130.00
10/19/2021Chardan CapitalLower TargetBuy$280.00 ➝ $160.00
10/19/2021LADENBURG THALM/SH SHReiterated RatingBuy$190.00
10/18/2021HC WainwrightLower TargetBuy$200.00 ➝ $100.00
5/25/2021Chardan CapitalReiterated RatingBuy$280.00
4/15/2021LADENBURG THALM/SH SHInitiated CoverageBuy$250.00
12/7/2020HC WainwrightReiterated RatingBuy
1/9/2020Cantor FitzgeraldReiterated RatingOverweight
(Data available from 12/23/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/27/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/26/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/25/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/24/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/24/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/23/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/23/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
BiomX logo
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Read More

Today's Range

Now: $0.62
Low: $0.57
High: $0.63

50 Day Range

MA: $0.72
Low: $0.49
High: $0.98

52 Week Range

Now: $0.62

Volume

117,777 shs

Average Volume

68,601 shs

Market Capitalization

$11.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

Frequently Asked Questions

What sell-side analysts currently cover shares of BiomX?

The following Wall Street analysts have issued reports on BiomX in the last twelve months: HC Wainwright, and Laidlaw.
View the latest analyst ratings for PHGE.

What is the current price target for BiomX?

0 Wall Street analysts have set twelve-month price targets for BiomX in the last year. Their average twelve-month price target is $22.50, suggesting a possible upside of 3,529.0%. Laidlaw has the highest price target set, predicting PHGE will reach $25.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $20.00 for BiomX in the next year.
View the latest price targets for PHGE.

What is the current consensus analyst rating for BiomX?

BiomX currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PHGE will outperform the market and that investors should add to their positions of BiomX.
View the latest ratings for PHGE.

What other companies compete with BiomX?

Other companies that are similar to BiomX include Kezar Life Sciences, MariMed, Omega Therapeutics, Exicure and Ayr Wellness. Learn More about companies similar to BiomX.

How do I contact BiomX's investor relations team?

BiomX's physical mailing address is 7 PINHAS SAPIR ST. FLOOR 2, NESS ZIONA L3, 7414002. The company's listed phone number is 972 7 23942377 and its investor relations email address is [email protected]. The official website for BiomX is www.biomx.com. Learn More about contacing BiomX investor relations.